Bulletin
Investor Alert

Corbus Pharmaceuticals Holdings Inc.

NAS: CRBP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Mar 1, 2021, 7:59 p.m.

/zigman2/quotes/201549545/composite

$

2.43

Change

+0.03 +1.25%

Volume

Volume 71,087

Quotes are delayed by 20 min

/zigman2/quotes/201549545/composite

Previous close

$ 2.18

$ 2.40

Change

+0.22 +10.09%

Day low

Day high

$2.23

$2.46

Open

52 week low

52 week high

$0.91

$9.78

Open

Sean F. Moran

Sean F. Moran is Chief Financial & Accounting Officer of Corbus Pharmaceuticals Holdings, Inc. and Chief Financial Officer of Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). Mr. Moran is also on the board of Video Advertising Bureau.

In his past career Mr. Moran occupied the position of Chief Financial Officer of Anika Therapeutics, Inc., Chief Financial Officer for Satcon Technology Corp., Chief Financial Officer & Senior Vice President at Celsion Corp., Chief Financial Officer of Echo Therapeutics, Inc. and Chief Financial Officer of Sontra Medical Corp. (a subsidiary of Echo Therapeutics, Inc.), Chief Financial Officer of Invivo Therapeutics Holdings Corp. and Chief Financial Officer at InVivo Therapeutics Corp. (a subsidiary of Invivo Therapeutics Holdings Corp.), Chief Financial Officer for Transport Pharmaceuticals, Inc. and Executive Vice President-Brand Sales at Viacom Media Networks, Inc.

Sean F. Moran received an undergraduate degree and an MBA from Babson College.

Transactions

Date Shares Transaction Value
12/21/2020 87,500   Disposition at $1.75 per share. 153,125
12/21/2020 87,500   Derivative/Non-derivative trans. at $1.4 per share. 122,500
12/18/2020 53,610   Disposition at $1.4 per share. 75,054
12/18/2020 53,610   Derivative/Non-derivative trans. at $1 per share. 53,610
12/16/2020 36,923   Disposition at $1.32 per share. 48,739
12/16/2020 36,923   Derivative/Non-derivative trans. at $0.17 per share. 6,276
05/14/2019 100   Acquisition at $7.12 per share. 712
03/14/2019 1,500   Acquisition at $6.67 per share. 10,005
05/15/2018 4,000   Acquisition at $5.77 per share. 23,080
03/14/2018 3,100   Acquisition at $6.6 per share. 20,460
11/10/2017 1,500   Acquisition at $7.04 per share. 10,560
08/11/2017 2,500   Acquisition at $5.91 per share. 14,775
05/11/2017 3,300   Acquisition at $6.14 per share. 20,262
03/13/2017 2,000   Acquisition at $9.6 per share. 19,200
12/02/2016 1,500   Acquisition at $7.2 per share. 10,800
09/08/2016 30,800   Acquisition at $5.12 per share. 157,696
08/26/2016 17,900   Acquisition at $3.92 per share. 70,168
08/18/2016 65,000   Acquisition at $3.48 per share. 226,200
08/17/2016 83,960   Acquisition at $3.19 per share. 267,832
05/19/2016 27,250   Acquisition at $2.37 per share. 64,582
05/18/2016 30,000   Acquisition at $2.39 per share. 71,700

Officers and Executives

Dr. Yuval Cohen
Chief Executive Officer & Director
Mr. Sean F. Moran
Chief Financial & Accounting Officer
Dr. Barbara White
Chief Medical Officer
Dr. Sergei Atamas
Executive Director-Research
Mr. Craig Millian
Chief Commercial Officer
Mr. Ross Lobell
Vice President-Regulatory Affairs
Mr. Alan F. Holmer
Chairman
Dr. Peter Salzmann
Independent Director
Mr. Avery W. Catlin
Independent Director
Dr. John Kenneth Jenkins
Independent Director
Ms. Rachelle Jacques
Independent Director
Link to MarketWatch's Slice.